Long-term efficacy data for Pfizer Inc.’s Elrexfio (elranatamab-bcmm) strengthens the bispecific antibody's position in the increasingly competitive space of BCMA-directed therapies for multiple myeloma. But apart from efficacy data, what may ultimately differentiate the growing number of BCMA-targeting therapies is how convenient they are to receive for patients.
Key Takeaways
-
Pfizer announced positive overall survival data at EHA for Elrexfio from the pivotal Phase II MagnetisMM-3 trial, with a median OS of 24.6 months.
- ...
At the European Hematology Association annual meeting, Pfizer announced the poster presentation at EHA of overall survival (OS) data from the pivotal Phase II MagnetisMM-3 study of Elrexfio in a...